GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longboard Pharmaceuticals Inc (NAS:LBPH) » Definitions » EPS without NRI

Longboard Pharmaceuticals (Longboard Pharmaceuticals) EPS without NRI : $-2.24 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Longboard Pharmaceuticals EPS without NRI?

Longboard Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.42. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.24.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -41.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Longboard Pharmaceuticals's EPS without NRI or its related term are showing as below:

LBPH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41.1   Med: -41.1   Max: -41.1
Current: -41.1

During the past 4 years, Longboard Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -41.10% per year. The lowest was -41.10% per year. And the median was -41.10% per year.

LBPH's 3-Year EPS without NRI Growth Rate is ranked worse than
87.6% of 1298 companies
in the Biotechnology industry
Industry Median: 5.15 vs LBPH: -41.10

Longboard Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.42. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.24.

Longboard Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2024 was $-0.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.24.


Longboard Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Longboard Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longboard Pharmaceuticals EPS without NRI Chart

Longboard Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS without NRI
-0.85 -1.93 -2.56 -2.39

Longboard Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.56 -0.65 -0.55 -0.62 -0.42

Competitive Comparison of Longboard Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, Longboard Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longboard Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longboard Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Longboard Pharmaceuticals's PE Ratio without NRI falls into.



Longboard Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Longboard Pharmaceuticals  (NAS:LBPH) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Longboard Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Longboard Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Longboard Pharmaceuticals (Longboard Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4275 Executive Square, Suite 950, La Jolla, CA, USA, 92037
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
Executives
Randall Kaye officer: CMO 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Jane Tiller director C/O LONGBOARD PHARMACEUTICALS, INC., 4275 EXECUTIVE DRIVE, SUITE 950, LA JOLLA CA 92037
Brandi Roberts officer: Chief Financial Officer 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Phillip M Schneider director GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Vincent Aurentz director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Kevin Robert Lind director, officer: President and CEO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Paul J Sekhri director C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Casey Lynch director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Le Goff Corinne director 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Arena Pharmaceuticals Inc 10 percent owner 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Philip Perera officer: Chief Medical Officer C/O LONGBOARD PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121

Longboard Pharmaceuticals (Longboard Pharmaceuticals) Headlines